CMT-NARS1

NARS1 | 2024

What Is CMT-NARS1?

CMT-NARS1 is a type of CMT caused by autosomal dominant mutations in the NARS1 gene. This gene provides instructions for making asparaginyl-tRNA synthetase, an enzyme that attaches the amino acid asparagine to its transfer RNA during protein synthesis. Mutations in the NARS1 gene disrupt this function, leading to impaired nerve signal transmission.

CMT-NARS1 is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

The age of symptom onset in CMT-NARS1 is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

CMT-NARS1 symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMT-NARS1 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT-NARS1

Classification
Unclassified Subtypes

Neuropathy Type
Axonal

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
NARS1

Gene Full Name
Asparaginyl-tRNA Synthetase 1

HGNC Gene Alias(es)
ASNRS, NARS

Chromosome
18q21.31

Zygosity of Responsible Variant
Heterozygous

Variant Mechanism
Toxic Gain of Function (GoF)

ClinVar Pathogenic Variants

View CMT-NARS1 ClinVar Variants

NARS1 OMIM Entry

NARS1 OMIM

More Info

CMT-NARS1 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Dominant NARS1 mutations causing axonal Charcot-Marie-tooth disease expand NARS1-associated diseases

Authors

Beijer, D., Marte, S., Li, J. C., De Ridder, W., Chen, J. Z., Tadenev, A., L. D., Miers, K. E., Deconinck, T., Macdonell, R., Marques Jr, W., De Jonghe, P., Pratt, S. L., Meyer-Schuman, R., Züchner, S., Antonellis, A., Burgess, R. W., Baets, J.

Publication Date
March 8, 2024

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.